Trials / Not Yet Recruiting
Not Yet RecruitingNCT07501052
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
An Evaluation of the Clinical Usability of the SCD411 Prefilled Syringe as a Proposed Biosimilar to US-licensed Eylea®
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR)
Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCD411 0.05mL (2mg) | Single intravitreal therapy (IVT) injection using a prefilled syringe (PFS) |
Timeline
- Start date
- 2026-05-08
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2026-03-30
- Last updated
- 2026-03-30
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07501052. Inclusion in this directory is not an endorsement.